OverviewSuggest Edit
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.
... Show more| Type | Public | |
| Founded | 1994 | |
| HQ | Lexington, US | Map |
| Website | agenusbio.com | |
| Employee Ratings | More |
Recent NewsAll News
- Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
- Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
- Agenus Awarded Grant to Enable QS-21 Innovations
- Thinking about buying stock in Agenus Inc., BlackBerry Limited, Caesars Entertainment Corp., New Age Beverages Corp., or Twitter, Inc.?
Key People/Management at Agenus
Garo Armen
PhD, Chairman and CEO
Jennifer Buell
PhD, Chief Operating Officer
Ozer Baysal
Chief Commercial Officer and Head of Human Resources
Alex Duncan
PhD, Chief Technology Officer and Head of Research
Christian Cortis
PhD, Chief Strategy Officer & Head of Finance
Report incorrect company information
Agenus Office Locations
Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Road
Berkeley, US
793 Heinz Ave
New York, US
149 Fifth Ave. Suite 500
Cambridge, GB
315 Science Park Milton Road
Report incorrect company information
Agenus Financials and Metrics
Agenus Revenue
Agenus's revenue was reported to be $42.88 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 12.8m |
Net income (Q3, 2018) | (33.7m) |
EBIT (Q3, 2018) | (26.1m) |
Market capitalization (15-Feb-2019) | 473.3m |
Closing stock price (15-Feb-2019) | 3.6 |
Cash (30-Sep-2018) | 46.2m |
EV | 440.3m |
Agenus's current market capitalization is $473.3 m.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 736.0k | 720.9k | 3.1m | 1.6m | 4.0m | 6.4m | 6.8m | 6.0m | 6.6m | 4.4m | 27.0m | 4.2m | 3.4m | 1.6m | 15.9m | 12.8m |
General and administrative expense | 3.6m | 5.2m | 5.8m | 4.9m | 5.5m | 8.0m | 6.4m | 9.2m | 7.1m | 8.1m | 7.8m | 8.1m | 8.1m | 8.9m | 9.5m | 9.2m |
R&D expense | 3.9m | 4.5m | 5.2m | 5.3m | 9.2m | 24.8m | 18.5m | 5.8m | 6.6m | 4.4m | 27.0m | 4.2m | 3.4m | 29.4m | 29.3m | 29.9m |
Operating expense total | 7.5m | 9.6m | 11.1m | 10.2m | 14.7m | 32.8m | 24.9m | 15.0m | 13.7m | 12.6m | 34.7m | 12.3m | 11.4m | 38.4m | 77.1m | 39.1m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 30.2m | 73.5m | 48.3m | 38.4m | 79.3m | 124.7m | 184.1m | 78.3m | 73.4m | 75.4m | 113.9m | 81.8m | 65.1m | 52.3m | 43.2m | 46.2m |
Accounts Receivable | 1.1k | 2.5m | 4.1m | 7.3m | 10.2m | 9.4m | 10.3m | 6.8m | 3.9m | 2.2m | 1.1m | 10.9m | 6.1m | |||
Inventories | 3.3k | 95.7k | 95.7k | 88.2k | 88.2k | 88.2k | 88.2k | 88.2k | 88.2k | 87.5k | 87.0k | 80.2k | 62.2k | 55.5k | 55.5k | |
Current Assets | 30.9m | 75.3m | 67.0m | 55.2m | 85.2m | 146.3m | 208.9m | 161.6m | 136.1m | 109.5m | 138.0m | 110.7m | 84.3m | 65.2m | 67.7m | 67.6m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (24.3m) | (357.5k) | (8.4m) | (16.5m) | (18.7m) | (59.2m) | (72.3m) | (31.8m) | (60.1m) | (100.9m) | (17.1m) | (48.8m) | (85.7m) | (54.3m) | (79.5m) | (113.2m) |
Depreciation and Amortization | 448.2k | 266.5k | 589.4k | 1.0m | 445.5k | 885.5k | 1.4m | 1.2m | 2.5m | 3.7m | 1.5m | 3.1m | 4.6m | 1.6m | 3.1m | 4.7m |
Inventories | 12.7k | (95.7k) | (95.7k) | 7.5k | 7.5k | 7.5k | 88.2k | 88.2k | 88.2k | 87.5k | 8.0k | 17.3k | 24.0k | 24.0k | ||
Accounts Payable | (269.4k) | 184.0k | (562.1k) | 35.2k | 2.3m | 797.8k | 1.3m | (2.3m) | 474.5k | (1.3m) | (1.1m) | (1.2m) | 1.0m | (2.8m) | 1.7m | 2.9m |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -16.9 x |
EV/CFO | -4.6 x |
Debt/Equity | -0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -1 x |
Report incorrect company information
Agenus Online and Social Media Presence
1.21k Twitter followers
Agenus has 1.21k Twitter Followers. The number of followers has increased 5.3% month over month and increased 8.6% quarter over quarter
Report incorrect company information
Agenus News and Updates
February 15, 2019
Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
LEXINGTON, Mass., Feb. 15, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that its Biotech Electronic Security Token (BEST), the...
January 24, 2019
Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead...
January 03, 2019
Agenus Awarded Grant to Enable QS-21 Innovations
LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill & Melinda Gates Foundation awarded it a grant ...
December 21, 2018
Thinking about buying stock in Agenus Inc., BlackBerry Limited, Caesars Entertainment Corp., New Age Beverages Corp., or Twitter, Inc.?
NEW YORK, Dec. 21, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGEN, BB, CZR, NBEV, and TWTR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 20, 2018
Agenus stock shoots up 60% after announcing drug development deal with Gilead
Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and …
December 20, 2018
Gilead, Agenus sign deal to develop immuno-oncology therapies
Gilead Sciences Inc has inked a
collaboration agreement with Agenus Inc for the
development and marketing of up to five novel immuno-oncology
therapies.
Report incorrect company information
Agenus Blogs
January 29, 2019
Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare
- The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation
October 20, 2018
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses
October 09, 2018
Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018
- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer
August 09, 2018
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- Cash milestones earned from Merck & Incyte
Agenus Company Life and Culture
Report incorrect company information
 Agenus Frequently Asked Questions
When was Agenus founded?
Agenus was founded in 1994.
Who are Agenus key executives?
Agenus's key executives are Garo Armen, Jennifer Buell and Ozer Baysal.
How many employees does Agenus have?
Agenus has 255 employees.
What is Agenus revenue?
Latest Agenus annual revenue is $42.9 m.
What is Agenus revenue per employee?
Latest Agenus revenue per employee is $168.1 k.
Who are Agenus competitors?
Competitors of Agenus include LogicBio Therapeutics, NextCure and ImmunoCellular Therapeutics.
Where is Agenus headquarters?
Agenus headquarters is located at 3 Forbes Road , Lexington.
Where are Agenus offices?
Agenus has offices in Lexington, Berkeley, New York and Cambridge.
How many offices does Agenus have?
Agenus has 4 offices.